πŸ‡ΊπŸ‡Έ FDA
Patent

US 11717565

Recombinant BCG overexpressing phoP-phoR

granted A61KA61K2039/522A61K2039/523

Quick answer

US patent 11717565 (Recombinant BCG overexpressing phoP-phoR) held by LTD. expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
LTD.
Grant date
Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/522, A61K2039/523, A61K35/74, A61K39/04